Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 277

1.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Marková J.

Neurodegener Dis Manag. 2019 Jan 18. doi: 10.2217/nmt-2018-0050. [Epub ahead of print]

PMID:
30657024
2.

Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group.

Lancet Neurol. 2018 Dec 13. pii: S1474-4422(18)30406-X. doi: 10.1016/S1474-4422(18)30406-X. [Epub ahead of print]

PMID:
30554828
3.

A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.

Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM.

CNS Drugs. 2018 Dec;32(12):1113-1129. doi: 10.1007/s40263-018-0577-6. Review.

PMID:
30361897
4.

Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Greene NZ, Wiley JL, Yu Z, Clowers BH, Craft RM.

Psychopharmacology (Berl). 2018 Nov;235(11):3289-3302. doi: 10.1007/s00213-018-5036-z. Epub 2018 Sep 20.

PMID:
30238130
5.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

Bramness JG, Dom G, Gual A, Mann K, Wurst FM.

Eur Addict Res. 2018;24(4):201-205. doi: 10.1159/000492757. Epub 2018 Aug 22.

PMID:
30134238
6.

Cannabis and Cannabinoids (PDQ®): Health Professional Version.

PDQ Integrative, Alternative, and Complementary Therapies Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2018 Aug 16.

7.

Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.

López-Valero I, Torres S, Salazar-Roa M, García-Taboada E, Hernández-Tiedra S, Guzmán M, Sepúlveda JM, Velasco G, Lorente M.

Biochem Pharmacol. 2018 Nov;157:275-284. doi: 10.1016/j.bcp.2018.08.023. Epub 2018 Aug 18.

PMID:
30125556
8.

Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.

Phan YHL, De Abreu Lourenco R, Haas M, van der Linden N.

Mult Scler Relat Disord. 2018 Oct;25:144-149. doi: 10.1016/j.msard.2018.07.020. Epub 2018 Aug 1.

PMID:
30077086
9.

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.

Karanges EA, Suraev A, Elias N, Manocha R, McGregor IS.

BMJ Open. 2018 Jul 3;8(7):e022101. doi: 10.1136/bmjopen-2018-022101.

10.

Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain.

Casey SL, Vaughan CW.

Medicines (Basel). 2018 Jul 1;5(3). pii: E67. doi: 10.3390/medicines5030067. Review.

11.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

12.

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.

Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G.

Medicines (Basel). 2018 Jun 21;5(3). pii: E59. doi: 10.3390/medicines5030059.

13.

Cannabinoids for Treatment of MS Symptoms: State of the Evidence.

Rice J, Cameron M.

Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Review.

PMID:
29923025
14.

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.

Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.

Int J Neurosci. 2018 Sep 13:1-10. doi: 10.1080/00207454.2018.1481066. [Epub ahead of print]

PMID:
29792372
15.

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.

Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group.

BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2.

16.

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

Celius EG, Vila C.

Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May.

17.

Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases.

Darkovska-Serafimovska M, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T.

J Pain Res. 2018 Apr 23;11:837-842. doi: 10.2147/JPR.S160556. eCollection 2018. Review.

18.

Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.

Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari T, Signoriello E.

Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23.

PMID:
29683408
19.

[Cannabinoid therapy in practice].

Rasche T, Emmert D, Stieber C, Mücke M, Conrad R.

Urologe A. 2018 May;57(5):558-562. doi: 10.1007/s00120-018-0636-0. Review. German.

PMID:
29651709
20.

Cannabis for Chronic Pain: Challenges and Considerations.

Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vázquez PA.

Pharmacotherapy. 2018 Jun;38(6):651-662. doi: 10.1002/phar.2115. Epub 2018 May 16. Review.

PMID:
29637590

Supplemental Content

Loading ...
Support Center